J. Gordon Foulkes

Dr. Gordon Foulkes Ph.D. has more than 25 years in the biopharmaceutical industry. Dr. Foulkes served as the founding CEO of Excaliard Pharmaceuticals from 2007 to 2009, and resumed that role in 2010 to lead the acquisition of Excaliard by Pfizer in 2011. He also served as Executive Chairman of Redwood BioSciences from 2012 until its acquisition by Catalent in 2014. From 2005 to 2010, Dr. Foulkes served as Managing Director at RiverVest Ventures, where he represented the RiverVest’s investments in Mpex (acquired by Axcan in 2011), CGI Pharmaceuticals (acquired by Gilead in 2010), Cabrellis (acquired by Pharmion in 2007 [now Celgene]), Conforma (acquired by Biogen in 2006), Excaliard (acquired by Pfizer in 2011) and MacroGenics (which completed an initial public offering in 2013). Previously, he headed R&D, in multiple biotechnology companies, including OSI Pharmaceuticals, acquired by Astellas for $4 billion in 2010 and Aurora Biosciences acquired by Vertex for $590M. He has had a lead role in securing more than 15 corporate partnerships, resulting in over $350 million in revenues, as well as directly participated in raising over $215 million in private and public offerings. Prior to joining Industry, Dr. Foulkes held academic positions at both MIT and the MRC (UK).

David Bullough, Ph.D.

CSO